Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMBXT9J)

• Drug Name: PMID24915291C38 Drug Info
• Synonyms: GTPL8145; PLS-123; BDBM50020476; 1431727-04-6

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 71556703
  TTD Drug ID: DMBXT9J

Molecule-Related Drug Atlas

Drug(s) Targeting Tyrosine-protein kinase Tec (PSCTK4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pyrazolo[4,3-c]pyridine derivative 2	DMCDFLQ	N. A.	N. A.	Patented	[2]
PMID24915291C31	DMN7QB8	Discovery agent	N.A.	Investigative	[1]

Drug(s) Targeting Tyrosine-protein kinase BTK (ATK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ibrutinib	DMHZCPO	Mantle cell lymphoma	2A85.5	Approved	[3]
Acalabrutinib	DM7GCVW	Mantle cell lymphoma	2A85.5	Approved	[4]
Zanubrutinib	DMJWRQP	Mantle cell lymphoma	2A85.5	Approved	[5]
GDC-0853	DMBEL3Q	Multiple sclerosis	8A40	Phase 3	[6]
ICP-022	DMU72KL	Chronic lymphocytic leukaemia	2A82.0	Phase 3	[7]
Pirtobrutinib	DMRG1X3	Chronic lymphocytic leukaemia	2A82.0	Phase 3	[8]
CC-292	DMJR9H0	Chronic lymphocytic leukaemia	2A82.0	Phase 2	[9]
BMS-986142	DMZB8AJ	Rheumatoid arthritis	FA20	Phase 2	[6]
LOU064	DME8O5K	Chronic idiopathic urticaria	EB00.1	Phase 2	[10]
BGB-3112	DMQCFSM	Follicular lymphoma	2A80	Phase 2	[11]

Drug(s) Targeting Tyrosine-protein kinase TXK (TXK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PMID24915291C31	DMN7QB8	Discovery agent	N.A.	Investigative	[1]
PMID17600705C23	DMJFOGW	Discovery agent	N.A.	Investigative	[12]

Drug(s) Targeting Epidermal growth factor receptor (EGFR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sorafenib	DMS8IFC	Hepatocellular carcinoma	2C12.02	Approved	[13]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[14]
Gefitinib	DM15F0X	Solid tumour/cancer	2A00-2F9Z	Approved	[15]
Erlotinib	DMCMBHA	Non-small-cell lung cancer	2C25.Y	Approved	[16]
Vandetanib	DMRICNP	Solid tumour/cancer	2A00-2F9Z	Approved	[17]
Dacomitinib	DMOH8VY	Non-small-cell lung cancer	2C25.Y	Approved	[18]
BIBW 2992	DMTKD7Q	Non-small-cell lung cancer	2C25.Y	Approved	[19]
SKI-758	DMQ8E9R	Ischemia	8B10-8B11	Approved	[20]
Epidermal growth factor	DMVONE6	Vulnerary	ND56.Z	Approved	[18]
Merimepodib	DM0HS92	Breast cancer	2C60-2C65	Approved	[21]

Drug(s) Targeting B lymphocyte kinase (BLK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pyrazolo[4,3-c]pyridine derivative 2	DMCDFLQ	N. A.	N. A.	Patented	[2]
PMID15546730C2	DMOPUIH	Discovery agent	N.A.	Investigative	[22]
PMID24915291C31	DMN7QB8	Discovery agent	N.A.	Investigative	[1]

Drug(s) Targeting Erbb4 tyrosine kinase receptor (Erbb-4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dacomitinib	DMOH8VY	Non-small-cell lung cancer	2C25.Y	Approved	[23]
RG7388	DMF5GZI	Acute myeloid leukaemia	2A60	Phase 3	[24]
CI-1033	DMSI8N3	Lymphoma	2A80-2A86	Phase 2	[17]
JI-101	DMM02VJ	Solid tumour/cancer	2A00-2F9Z	Phase 2	[25]
JNJ-26483327	DMSQ3AZ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[26]
HDS-029	DMLRUVA	Discovery agent	N.A.	Investigative	[27]

Drug(s) Targeting ERBB2 messenger RNA (HER2 mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
HKI-272	DM6QOVN	Breast cancer	2C60-2C65	Phase 3	[28]
BMS-690514	DMX302C	Chronic pain	MG30	Phase 2	[29]
3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione	DMDO175	Discovery agent	N.A.	Investigative	[30]
3,4-diphenyl-1H-pyrrole-2,5-dione	DMPK6YT	Discovery agent	N.A.	Investigative	[30]
3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione	DMGC7RY	Discovery agent	N.A.	Investigative	[30]
BMS-536924	DMXJB4N	Discovery agent	N.A.	Investigative	[31]
3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione	DM3EV9N	Discovery agent	N.A.	Investigative	[30]
Geldanamycin-estradiol hybrid	DMUSJ96	Discovery agent	N.A.	Investigative	[32]
CL-387785	DMLKFZC	Discovery agent	N.A.	Investigative	[27]
HDS-029	DMLRUVA	Discovery agent	N.A.	Investigative	[27]

Drug(s) Targeting Tyrosine-protein kinase BMX (BMX)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PMID24915291C31	DMN7QB8	Discovery agent	N.A.	Investigative	[1]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
B lymphocyte kinase (BLK)	TTNDSC3	BLK_HUMAN	Inhibitor	[1]
Epidermal growth factor receptor (EGFR)	TTGKNB4	EGFR_HUMAN	Inhibitor	[1]
ERBB2 messenger RNA (HER2 mRNA)	TTR5TV4	ERBB2_HUMAN	Inhibitor	[1]
Erbb4 tyrosine kinase receptor (Erbb-4)	TT0JESD	ERBB4_HUMAN	Inhibitor	[1]
Tyrosine-protein kinase BMX (BMX)	TTN2I9E	BMX_HUMAN	Inhibitor	[1]
Tyrosine-protein kinase BTK (ATK)	TTGM6VW	BTK_HUMAN	Inhibitor	[1]
Tyrosine-protein kinase Tec (PSCTK4)	TT1ZV49	TEC_HUMAN	Inhibitor	[1]
Tyrosine-protein kinase TXK (TXK)	TT8M1DP	TXK_HUMAN	Inhibitor	[1]

References

• [1] Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity. J Med Chem. 2014 Jun 26;57(12):5112-28.
• [2] Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1948).
• [4] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] Clinical pipeline report, company report or official report of InnoCare Pharma.
• [8] Targeting BTK in CLL: Beyond Ibrutinib. Curr Hematol Malig Rep. 2019 Jun;14(3):197-205.
• [9] Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans. J Pharmacol Exp Ther. 2013 Aug;346(2):219-28.
• [10] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [11] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [12] N-4-Pyrimidinyl-1H-indazol-4-amine inhibitors of Lck: indazoles as phenol isosteres with improved pharmacokinetics. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4363-8.
• [13] Nasopharyngeal carcinoma: Current treatment options and future directions. J Nasopharyng Carcinoma, 2014, 1(16): e16.
• [14] Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7.
• [15] Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer. 2004 Feb 9;90(3):566-72.
• [16] Quantitative prediction of fold resistance for inhibitors of EGFR. Biochemistry. 2009 Sep 8;48(35):8435-48.
• [17] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [18] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
• [19] Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
• [20] Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76.
• [21] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [22] Discovery of novel 2-(aminoheteroaryl)-thiazole-5-carboxamides as potent and orally active Src-family kinase p56(Lck) inhibitors. Bioorg Med Chem Lett. 2004 Dec 20;14(24):6061-6.
• [23] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7422).
• [24] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1799).
• [25] A pilot study of JI-101, an inhibitor of VEGFR-2, PDGFR-, and EphB4 receptors, in combination with everolimus and as a single agent in an ovarian cancer expansion cohort.Invest New Drugs.2015 Dec;33(6):1217-24.
• [26] National Cancer Institute Drug Dictionary (drug id 596693).
• [27] Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB... J Med Chem. 2006 Feb 23;49(4):1475-85.
• [28] Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19936-41.
• [29] Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2. J Pharm Sci. 2010 Aug;99(8):3579-93.
• [30] Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
• [31] Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitum... J Med Chem. 2005 Sep 8;48(18):5639-43.
• [32] Synthesis and evaluation of geldanamycin-estradiol hybrids. Bioorg Med Chem Lett. 1999 May 3;9(9):1233-8.